Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.

Biopharma giant Biocon reported a 153 per cent year-on-year (YoY) rise in consolidated net profit to Rs. 344 crore in the fourth quarter of FY25, compared to Rs. 136 crore in Q4 FY24.

Biocon’s total consolidated revenue for Q4 FY25 was Rs. 4,454 crore, up from Rs. 3,966 crore in Q4 FY24. EBITDA stood at Rs. 1,115 crore, marking a 16 per cent rise, with a maintained margin of 25 per cent.

The Generics business reported the strongest performance for the year in Q4FY25, driven largely by the sale of launch quantities of Lenalidomide capsules in the U.S., following a settlement with the innovator company. The Company also launched Dasatinib tablets and Triamterne capsules in the U.S. during the quarter.

Q4 FY25 growth was also supplemented by the UK launch of Biocon’s first GLP-1 product, Liraglutide, under the brand names, Liraglutide Biocon to treat diabetes and Biolide for chronic weight management. A distribution partnership for Liraglutide executed for retail markets in the UK and the Netherlands will enable the Company to expand the product’s reach in the region.

The Company also commenced supplies of Tacrolimus to China, with its regional partner expected to initiate commercialization in the first quarter of FY26. During the quarter, product approvals for Everolimus (Zortress®) tablets and Norepinephrine Bitartrate injection were secured in the U.S.

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24. However, net profit for the year declined marginally by 0.9 per cent to Rs. 1,013.3 crore from Rs. 1,022.5 crore.

The Board has also approved a plan to raise up to Rs. 4,500 crore through various modes, including qualified institutional placement, rights issue, or other permissible routes.

“The Biocon Group ended the year with a strong performance across its businesses. The launch of Liraglutide in the UK market heralded our entry into the GLP-1 therapy segment. Our Biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of USD 200 million each in FY25. We also launched our fifth biosimilar product Yesintek (bUstekinumab) in the U.S. market. This quarter marked the expansion of Syngene’s biologics manufacturing footprint through an acquisition of a state-of-the-art manufacturing facility in the U.S. “FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence,” said Kiran Mazumdar-Shaw, Chairperson, Biocon Group.

Siddharth Mittal, CEO and Managing Director of Biocon, attributed the generics division’s growth to new launches such as Lenalidomide and Dasatinib in the US, supported by moderate growth in APIs. “We are focused on strategically expanding our differentiated GLP-1 portfolio into new markets, positioning us for long-term growth. We also expect a recovery in the API business in FY26, aided by cost improvements, operational efficiencies, and new capacity additions,” he said.

Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said performance was driven by market share gains in the US and key tender wins in emerging markets. “We are well positioned to launch five new products in the next 12–18 months and expand patient access,” he added.

Peter Bains, CEO and Managing Director of Syngene International, noted that Q4 revenue grew 11 per cent YoY and 8 per cent sequentially, crossing Rs. 1,000 crore in quarterly revenue for the first time. “While global market dynamics remain uncertain, the positive momentum that drove Syngene’s growth in the latter half of FY25 is expected to continue into FY26,” he said.

The Board has recommended a final dividend of Rs. 0.50 per share (10 per cent of face value) for the financial year ended 31 March 2025.